hers glp 1 super bowl commercial Hims & is rolling out a new ad for its GLP-1s this year — and plenty of companies are joining it this time around. Ro, Novo Nordisk, and Eli Hims and Hers Super Bowl

In one such study, Joo et al found no difference between 692 GLP-1RA and 289 SGLT-2I users in DR by clinical worsening, using ICD-10 codes, or by need for procedures after propensity score matching across baseline variables

J Neurosci 34:53225334

[DOI] [PubMed] [Google Scholar] [27].Teppema LJ, Veening JG, Kranenburg A, Dahan A, Berkenbosch A, Olievier C

Current consensus is that GLP-1 treatment benefits outweigh the risk of EWDR: the drugs reduce the risk of further microvascular damage from poor glycemic control and reduce the chance of death from cardiovascular disease, while the impact on DR is short-lived and can be treated